Literature DB >> 6807695

Nitroglycerin for ergotism. Experimental studies in vitro and in migraine patients and treatment of an overt case.

P Tfelt-Hansen, J R Ostergaard, I Gøthgen, E Jacobsen, J P Rasmussen, B Husum.   

Abstract

Ergotamine was used to induce arterial contraction in vitro (measurement of isometric tension in segments from 3 human temporal arteries) and in vivo (peripheral systolic blood pressure measured by strain gauge plethysmography in 5 migrainous patients). In both these models of ergotism, the directly acting vasodilator nitroglycerine (NTG) effectively relieved the ergotamine-induced arterial contractions. A case of ergotism treated successfully with NTG infusion is reported. The diagnosis was based on history and measurement of peripheral systolic blood pressure by strain gauge plethysmography. The latter technique was also used to monitor the response to treatment for 20 h. Blood levels of ergotamine during ergotism were in the therapeutic range. Possible explanations for this finding are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6807695     DOI: 10.1007/BF00542453

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  [Not Available].

Authors:  E ROTHLIN; A CERLETTI
Journal:  Helv Physiol Pharmacol Acta       Date:  1949-11

2.  Peripheral arterial insufficiency during ergotamine treatment. Course of disease, angiographical findings, and treatment by phenoxybenzamine.

Authors:  I Hessov; C Kromann-Andersen; B Madsen
Journal:  Dan Med Bull       Date:  1972-10

3.  Extraction procedure for measuring anticonvulsant drugs by liquid chromatography.

Authors:  S Y Chu; L Oliveras; S Deyasi
Journal:  Clin Chem       Date:  1980-03       Impact factor: 8.327

4.  Ergotamine abuse. Do patients benefit from withdrawal?

Authors:  P Tfelt-Hansen; A Krabbe
Journal:  Cephalalgia       Date:  1981-03       Impact factor: 6.292

5.  Drug interactions of the components of Optalidon after oral administration.

Authors:  D Lavene; J Longchampt; M F Guillaume; J L Kiger
Journal:  Int J Clin Pharmacol Biopharm       Date:  1976-06

6.  Regional differences in the responsiveness of isolated arteries from cattle, dog and man.

Authors:  E Müller-Schweinitzer; H Weidmann
Journal:  Agents Actions       Date:  1977-09

7.  Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms.

Authors:  Annette Aebelholt Krabbe; Jes Olesen
Journal:  Pain       Date:  1980-04       Impact factor: 6.961

8.  Ergot intoxication: historical review and description of unusual clinical manifestations.

Authors:  G C Merhoff; J M Porter
Journal:  Ann Surg       Date:  1974-11       Impact factor: 12.969

9.  Vasodilator therapy after cardiac surgery: a review of the efficacy and toxicity of nitroglycerin and nitroprusside.

Authors:  J A Kaplan; D C Finlayson; S Woodward
Journal:  Can Anaesth Soc J       Date:  1980-05

10.  Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; J Heikkilä; N Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

View more
  3 in total

1.  Refractory caffeine and ergot-induced cervico-cerebral vasospasm and stroke treated with combined medical and endovascular approach.

Authors:  Megan Miller; Avinash B Kumar; Charles R Callison
Journal:  Neuroradiology       Date:  2011-04-06       Impact factor: 2.804

Review 2.  What can be learned from the history of recurrence in migraine? A comment.

Authors:  Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-08-25       Impact factor: 7.277

Review 3.  Polypharmacy in Older Adults With Hypertension: A Comprehensive Review.

Authors:  Bertrand N Mukete; Keith C Ferdinand
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-27       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.